CN107920997A - 富马酸二甲酯颗粒和其药物组合物 - Google Patents

富马酸二甲酯颗粒和其药物组合物 Download PDF

Info

Publication number
CN107920997A
CN107920997A CN201680047251.2A CN201680047251A CN107920997A CN 107920997 A CN107920997 A CN 107920997A CN 201680047251 A CN201680047251 A CN 201680047251A CN 107920997 A CN107920997 A CN 107920997A
Authority
CN
China
Prior art keywords
dmf
dosage form
inner layer
controlled release
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680047251.2A
Other languages
English (en)
Chinese (zh)
Inventor
P·布拉斯
E·厄达姆
S·B·卡基
W·F·吉斯曼
梁绰睿
林毅清
A·特雷蒙托兹
P·扎瓦纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Than Ao Gen Ma Co
Original Assignee
Than Ao Gen Ma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Than Ao Gen Ma Co filed Critical Than Ao Gen Ma Co
Publication of CN107920997A publication Critical patent/CN107920997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680047251.2A 2015-06-17 2016-06-15 富马酸二甲酯颗粒和其药物组合物 Pending CN107920997A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181061P 2015-06-17 2015-06-17
US62/181,061 2015-06-17
PCT/US2016/037486 WO2016205270A1 (en) 2015-06-17 2016-06-15 Dimethyl fumarate particles and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CN107920997A true CN107920997A (zh) 2018-04-17

Family

ID=56292916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680047251.2A Pending CN107920997A (zh) 2015-06-17 2016-06-15 富马酸二甲酯颗粒和其药物组合物

Country Status (13)

Country Link
US (2) US11291642B2 (https=)
EP (1) EP3310341A1 (https=)
JP (2) JP2018517735A (https=)
KR (1) KR20180018711A (https=)
CN (1) CN107920997A (https=)
AU (2) AU2016279997B2 (https=)
CA (1) CA2989581A1 (https=)
EA (1) EA201890068A1 (https=)
HK (1) HK1254054A1 (https=)
IL (1) IL256296A (https=)
MA (1) MA42196A (https=)
MX (1) MX387092B (https=)
WO (1) WO2016205270A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113165338A (zh) * 2018-10-05 2021-07-23 埃斯普投资有限公司 包含水溶性纤维素醚的光滑的高固体膜包衣组合物及其制备工艺
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016344673A1 (en) * 2015-10-28 2018-05-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
JP6902043B2 (ja) * 2016-02-11 2021-07-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチルを含む医薬ビーズ製剤
CA3075720A1 (en) * 2017-10-02 2019-04-11 Novartis Ag Method for preparing a pharmaceutical product
WO2019194826A1 (en) 2018-04-06 2019-10-10 Hewlett-Packard Development Company, L.P. Three-dimensional (3d) object printing based on build material permeability
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
EP3917500A2 (en) * 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
JP2022525482A (ja) * 2019-03-20 2022-05-16 リンドラ セラピューティクス， インコーポレイティド 胃内滞留剤形用のコーティング
MX2021011314A (es) * 2019-03-20 2021-12-10 Lyndra Therapeutics Inc Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica.
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
AU2022285951A1 (en) 2021-06-04 2024-01-04 Zim Laboratories Limited Delayed release compositions of dimethyl fumarate
US11590071B2 (en) * 2021-07-06 2023-02-28 King Abdulaziz University Injectable drug delivery implant composition and method of use thereof
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025090498A1 (en) * 2023-10-23 2025-05-01 Isp Investments Llc Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037342A2 (en) * 2004-10-08 2006-04-13 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080233185A1 (en) * 2001-01-12 2008-09-25 Fumapharm Ag Fumaric Acid Derivatives as NF-kappaB Inhibitor
CN102149369A (zh) * 2008-04-18 2011-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
US8609136B2 (en) * 2006-01-18 2013-12-17 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP2012514623A (ja) * 2009-01-09 2012-06-28 フォーワード・ファルマ・アクティーゼルスカブ １またはそれ以上のフマル酸エステルを含む医薬組成物
WO2010079222A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
SMT201800098T1 (it) * 2011-06-08 2018-03-08 Biogen Ma Inc Processo per la preparazione di dimetilfumarato cristallino e con purezza elevata
RU2014125430A (ru) * 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
IN2013MU03070A (https=) * 2013-09-25 2015-07-17 Glenmark Pharmaceuticals Ltd
EP3079663A1 (en) * 2013-12-13 2016-10-19 Biogen MA Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080233185A1 (en) * 2001-01-12 2008-09-25 Fumapharm Ag Fumaric Acid Derivatives as NF-kappaB Inhibitor
WO2006037342A2 (en) * 2004-10-08 2006-04-13 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8609136B2 (en) * 2006-01-18 2013-12-17 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
CN102149369A (zh) * 2008-04-18 2011-08-10 因泰克制药有限公司 卡比多巴/左旋多巴胃滞留给药
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《药学进展》: "富马酸二甲酯胶囊剂在美国获准用于治疗多发性硬化症", 《药学进展》 *
GEORGE S.PETROKA: ""Occupational Toxicology,IH and Containment Challgenges associated with an API"", 《HTTP://WWW.PHARMAFORUMPAGE.COM/PHARMAFORUMWP/WPCONTENT/UPLOADS/2015/06/DMFU-CHALLENGES_PHARMAFORUM2015_PETROKA_BALLINGER_MEINERS_HEMP.PDF》 *
张超云等: "《药剂学》", 30 October 2013, 辽宁大学出版社 *
胡崇茂: "《药用辅料 薄膜包衣预混剂生产和应用》", 31 May 2014, 中国医药科技出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113165338A (zh) * 2018-10-05 2021-07-23 埃斯普投资有限公司 包含水溶性纤维素醚的光滑的高固体膜包衣组合物及其制备工艺
CN113165338B (zh) * 2018-10-05 2023-04-11 埃斯普投资有限公司 包含水溶性纤维素醚的光滑的高固体膜包衣组合物及其制备工艺
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用

Also Published As

Publication number Publication date
WO2016205270A1 (en) 2016-12-22
JP2018517735A (ja) 2018-07-05
CA2989581A1 (en) 2016-12-22
MA42196A (fr) 2018-04-25
AU2016279997B2 (en) 2021-10-21
WO2016205270A8 (en) 2017-01-19
HK1254054A1 (zh) 2019-07-12
US20220362195A1 (en) 2022-11-17
MX387092B (es) 2025-03-19
KR20180018711A (ko) 2018-02-21
AU2016279997A1 (en) 2018-01-18
US11291642B2 (en) 2022-04-05
AU2022200155A1 (en) 2022-02-10
US20190070143A1 (en) 2019-03-07
MX2017016509A (es) 2018-08-16
EP3310341A1 (en) 2018-04-25
EA201890068A1 (ru) 2018-09-28
IL256296A (en) 2018-02-28
JP2022042512A (ja) 2022-03-14

Similar Documents

Publication Publication Date Title
US20220362195A1 (en) Dimethyl fumarate particles and pharmaceutical compositions thereof
CN101022788B (zh) 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
KR101147666B1 (ko) 위 정체 제제
Al-Kasmi et al. Mechanical microencapsulation: The best technique in taste masking for the manufacturing scale-Effect of polymer encapsulation on drug targeting
KR100514467B1 (ko) 신속 붕괴 펠릿
US10172794B2 (en) Controlled release dosage form for once daily administration of dimethyl fumarate
KR20180090881A (ko) 위 체류 시스템을 위한 기하 구성형태
KR101412401B1 (ko) 삼투 펌프 제어 방출 정제 및 이의 제조방법
CA2698330A1 (en) Galenical formulations of organic compounds
JP2005524654A (ja) ３８Ｎ／ｃｍ２以下の抗張力を持った核錠と軟質の核錠を保護する被膜を持った投薬物
Porwal et al. Decades of research in drug targeting using gastroretentive drug delivery systems for antihypertensive therapy
CN106619520B (zh) 一种右兰索拉唑钠的干混悬剂及其制备方法
CN104352441A (zh) 一种富马酸二甲酯肠溶微丸及其制备方法
CN107308127A (zh) 双氯芬酸钠多单元缓释微丸片
EP2161019A1 (en) Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
CN101862305A (zh) 一种盐酸氨溴索缓释微丸及制备方法
CN103751137A (zh) 雷诺嗪多单元缓释微丸片
CN103800291B (zh) 一种对氨基水杨酸钠肠溶微丸制剂
CN101287453A (zh) 包含头孢菌素的毫微粒和控制释放组合物
CN1729964B (zh) 一种具有膨胀核心的掩味微囊及制备方法
CN1568954A (zh) 美沙拉嗪结肠定位释药微丸制剂及其制备方法
Gautam et al. A review on microspheres: Types, methods and evaluation.
Naveena et al. Preparation And Evaluation of Floating Microsphere J Clinical Case Studies and Review Reports. 1 (1): 1
Kulkarni et al. Gastroretentive Drug Delivery Systems
CN117942314A (zh) 一种罗红霉素颗粒剂的包衣层、颗粒剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180417